1 / 11

Using  Nanotechnology  to  Change  Cancer  Care

Using  Nanotechnology  to  Change  Cancer  Care. Maryland Technology Day 28  February  2013. The  Promise  of  Cancer  Nanomedicines   Deliver  potent  an6-­‐cancer  agents  directly  to  the  site  of  disease  . Reduced  or  no  toxicity  

anka
Télécharger la présentation

Using  Nanotechnology  to  Change  Cancer  Care

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Using  Nanotechnology  to  Change  Cancer  Care MarylandTechnologyDay 28  February  2013

  2. The  Promise  of  Cancer  Nanomedicines   Deliver  potent  an6-­‐cancer  agents  directly  to  the  site  of  disease   Reduced  or  no  toxicity   Improved  efficacy Ø Ø Treat  cancer  as  a  medical  disease  first   Dose  intravenously  prior  to  surgery   Limited  biodistribu6on  due  to  leaky  tumor  blood  vessels     Reduce  tumor  burden  by  tumor-­‐targeted  nanomedicines   Reduce  or  eliminate  sophis6cated  surgical  procedures   Improve  pa6ent  outcome   Ø Ø Ø Ø Ø Treat  cancer  as  a  chronic  medical  disease   Treat  periodically  to  destroy  nascent  tumor  neovasculature   Suppress  metasta6c  disease   2   Ø Ø

  3. Design  of  Aurimune  (CYT-­‐6091): Waterabsorbedby PEG-THIOLshields nanoparticlefrom immunedetection 3

  4. Safe,  Targeted  Delivery:  Size  MaGers   Too  Large  for  Toxic  Side  Effects.    Aurimune  is   small  enough  to  safely  travel  through  healthy   blood  vessels,  but  too  large  to  pass  through  blood   vessel  walls  into  healthy  6ssues  and  organs,     resul6ng  in  reduced  toxicity. Small    Enough  to  Exit  Tumor  Vessels.    All  solid   tumors  are  fueled  by  new,  “leaky”  blood  vessels  that   have  gaps  in  their  walls.    When  Aurimune  reaches   these  “leaky”  vessels,  the  nanopar6cles  are  small   enough  to  pass  through  these  walls  into  their  target,   the  tumor.   Due  to  its  engineered  nanometer  size  and  targeted  capabiliJes,   Aurimune  is  able  to  reduce  toxicity  and  increase  efficacy.   4

  5. Clinical  Grade  Aurimune   Current  produc6on  capacity  scaled  10-­‐fold  from  Phase  I  to  Phase  II   Process  is  robust,  reproducible  and  cost  effec6ve     Solved  manufacturing  challenge  for  a  nanomedicine   3-­‐year  shelf  life  as  a  freeze  dried  product   Ø Ø Ø 5

  6. Aurimune  Phase  I  Trial:    Clinical  ObservaJons   Safe,  systemic  delivery.    Delivered  1.2  mg  of  TNF  with  no   dose  limi6ng  toxicity ØNo  Hypotension,  the  dose-­‐limi6ng  toxicity  associated  with  TNF   use  in  man   ØNo  Serious  Adverse  Events  that  were  unexpected  and  related  to   treatment   Tumor  targeted.    Drug  accumula6on  at  tumor  sites ØGold  par6cles  seen  in  tumors  but  few  if  any  in  healthy  6ssues   6  

  7. Electron  Micrographs*  of  a  PaJent’s  Biopsies Pa6ent  diagnosed  with  inoperable  breast  cancer Ø    Pa6ent  had  no  prior  treatment;  samples  taken  24h  aYer  treatment   Ø    Drug  accumulated  in  tumor,  not  in  healthy  breast  6ssue HealthyBreast Tumor *Magnification=20,000x 7

  8. Montefiore’s  Commitment  to  Nanomedicine   8  

  9. The  Pipeline:  Leveraging  PlaWorm’s  Flexibility     PlaWorm  allows  for  mulJple  cancer  treatments  for  mulJple  cancer  indicaJons   9

  10. Blueprint  of  Gold-­‐Based,  Drug-­‐Rescue  Nanomedicine   PEG-­‐THIOL   TNF:     A  targeted  VDA   AstraZeneca  Proprietary   Drug   10  

  11. CytImmune  Summary   Aurimune  will  transform  current  “medieval”  approaches  to  cancer  treatment   Aurimune  plus  chemotherapies  aims  to  significantly  improve  responses  rates   Aurimune  is  not  another  “me  too”  drug;  it’s  a  quantum  leap  forward  in  cancer  care   Aurimune  is  the  first-­‐in-­‐a-­‐family  of  nanomedicines   CytImmune  will  create  a  pipeline  of  cancer  nanomedicines   CytImmune’s  technology  will  change  the  way  we  treat  cancer 11  

More Related